NasdaqCM:DARE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. More Details


Snowflake Analysis

Slightly overvalued with imperfect balance sheet.

Share Price & News

How has Daré Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DARE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.2%

DARE

-2.5%

US Medical Equipment

-3.1%

US Market


1 Year Return

25.0%

DARE

14.6%

US Medical Equipment

12.7%

US Market

Return vs Industry: DARE exceeded the US Medical Equipment industry which returned 14.6% over the past year.

Return vs Market: DARE exceeded the US Market which returned 12.7% over the past year.


Shareholder returns

DAREIndustryMarket
7 Day-8.2%-2.5%-3.1%
30 Day-8.2%-0.06%-2.9%
90 Day-1.9%13.9%8.2%
1 Year25.0%25.0%15.6%14.6%15.3%12.7%
3 Year-67.8%-67.8%71.4%67.0%37.8%28.5%
5 Yearn/a149.1%130.4%90.9%69.4%

Price Volatility Vs. Market

How volatile is Daré Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Daré Bioscience undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DARE ($1.01) is trading below our estimate of fair value ($19.19)

Significantly Below Fair Value: DARE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DARE is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: DARE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DARE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DARE is overvalued based on its PB Ratio (92.6x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Daré Bioscience forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

51.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DARE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DARE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DARE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if DARE's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if DARE's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DARE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Daré Bioscience performed over the past 5 years?

-39.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DARE is currently unprofitable.

Growing Profit Margin: DARE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DARE is unprofitable, and losses have increased over the past 5 years at a rate of 39.3% per year.

Accelerating Growth: Unable to compare DARE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DARE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: DARE has a negative Return on Equity (-5987.37%), as it is currently unprofitable.


Next Steps

Financial Health

How is Daré Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: DARE's short term assets ($7.8M) exceed its short term liabilities ($6.1M).

Long Term Liabilities: DARE's short term assets ($7.8M) exceed its long term liabilities ($2.2M).


Debt to Equity History and Analysis

Debt Level: DARE's debt to equity ratio (118%) is considered high.

Reducing Debt: Insufficient data to determine if DARE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DARE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DARE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 60.2% each year


Next Steps

Dividend

What is Daré Bioscience current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DARE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DARE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DARE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DARE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DARE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Sabrina Johnson (53 yo)

5.33yrs

Tenure

US$628,753

Compensation

Ms. Sabrina Martucci Johnson is the Founder and Chief Executive Officer of Dare Bioscience and serves as its President. Ms. Johnson serves as Secretary and Treasurer at Kyalin Biosciences, Inc. Ms. Johnson ...


CEO Compensation Analysis

Compensation vs Market: Sabrina's total compensation ($USD628.75K) is about average for companies of similar size in the US market ($USD601.89K).

Compensation vs Earnings: Sabrina's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Sabrina Johnson
President5.33yrsUS$628.75k3.05%
$ 971.7k
Lisa Walters-Hoffert
CFO & Secretary3.17yrsUS$412.72k1.41%
$ 447.9k
Mark Walters
Vice President of Operations5.67yrsno data0%
$ 0
MarDee Haring-Layton
Vice President of Accounting & Financeno datano datano data
David Friend
Chief Scientific Officer2.25yrsno datano data
John Fair
Chief Strategy Officer2.33yrsno datano data
Mary Jarosz
Global Head of Regulatory Affairs2.25yrsno datano data
John Katsilometes
Controllerno datano datano data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Management: DARE's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sabrina Johnson
President5.33yrsUS$628.75k3.05%
$ 971.7k
William Rastetter
Chairman of the Board6.67yrsUS$83.50k0.033%
$ 10.4k
Robert Langer
Member of Scientific Advisory Board1.5yrsno datano data
Susan Kelley
Independent Director5.92yrsUS$64.31k0%
$ 0
Cheryl Blanchard
Independent Director0.83yrUS$37.51kno data
Robin Steele
Independent Director3.17yrsUS$66.81k0.78%
$ 248.6k
Jessica Grossman
Independent Director2.42yrsUS$61.36k0%
$ 0
Gregory Matz
Independent Director2yrsUS$70.91k0.0016%
$ 503.5

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: DARE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 89.1%.


Top Shareholders

Company Information

Daré Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Daré Bioscience, Inc.
  • Ticker: DARE
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$31.868m
  • Shares outstanding: 31.55m
  • Website: https://www.darebioscience.com

Number of Employees


Location

  • Daré Bioscience, Inc.
  • 3655 Nobel Drive
  • Suite 260
  • San Diego
  • California
  • 92122
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DARENasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2017
1221DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2017

Biography

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. The company intends to develop therapies in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 07:10
End of Day Share Price2020/09/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.